SEC Filing Summary: Rexahn Pharmaceuticals, Inc. (Form 8-K)
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Rexahn Pharmaceuticals, Inc. (not Opus Genetics, Inc.) on May 20, 2009, reporting events occurring on May 19, 2009. The filing details the entry into a material definitive agreement regarding a private securities offering.
Key Financial Metrics and Transaction Details
The company executed a Securities Purchase Agreement with a single institutional investor. The transaction structure includes:
- Common Stock Issued: 2,857,143 shares.
- Warrants Issued:
- Series I: 2,222,222 warrants at $1.05 exercise price (exercisable within 90 days).
- Series II: 1,866,666 warrants at $1.25 exercise price (exercisable 6 months to 3 years).
- Series III: 1,555,555 warrants at $1.50 exercise price (exercisable 6 months to 5 years).
- Net Proceeds: Approximately $2.82 million after deducting placement fees and estimated expenses.
- Placement Agent Fees: Rodman & Renshaw, LLC received a 6% fee on gross proceeds plus 142,857 warrants at $1.3125 per share.
Note: This filing does not provide revenue, profit, cash flow, margins, debt, or liquidity metrics for the company's operations.
Material Changes
The primary material change is the capital raise via the issuance of equity and warrants to a single institutional investor. This transaction increases the company's cash position by approximately $2.82 million and introduces significant potential dilution through the issuance of common stock and warrants covering over 5.6 million shares.
Outlook, Risks, and Management Commentary
The offering was conducted on a "best efforts" basis pursuant to a shelf registration statement (Form S-3) declared effective in August 2008. The filing incorporates by reference a press release and legal opinions but does not contain specific forward-looking guidance, management commentary on future operations, or a discussion of risks beyond the standard disclosures inherent in a securities offering.
Investor Verification Checklist
- Verify the final closing date and actual net proceeds received versus the estimated $2.82 million.
- Confirm the identity of the single institutional investor and any related party status.
- Review the full text of the Securities Purchase Agreement (Exhibit 10.1) for specific covenants or restrictions.
- Monitor the exercise of the Series I warrants, which have a short 90-day window, to assess immediate dilution impact.
- Check subsequent filings for the prospectus supplement referenced in the document.